ClinicalTrials.gg
CompletedNCT00195468Updated Mar 8, 2011

Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus

A Phase 4 interventional study of CYCLOSPORINE in Kidney Failure and Graft vs Host Disease, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-08.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Planned enrollment
2nd of 36
280 · median 30
Started
2004
with 2 others
Phase 4
8 of 37
none open now
Registered
5th of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 2nd largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2004, is one of 8 in phase 4, and was the 5th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

Compare kidney function as measured by calculated creatinine clearance (using the method by Nankivell)1 at 12 months after transplantation in subjects receiving induction therapy with cyclosporine microemulsion (CsA) and Rapamune followed by CsA dose reduction (Group I) with subjects receiving induction therapy with CsA and Rapamune followed by CsA discontinuation (Group II).

03

Conditions studied

  • Kidney Failure
  • Graft vs Host Disease

Keywords

  • Kidney Failure
  • Transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with end-stage renal disease scheduled to receive a primary or secondary renal allograft from a cadaveric donor, from a living-unrelated donor, or a living-related HLA-mismatched donor. Subjects must be at least 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Subjects with active major infection, including active or C infection, decreased , elevated lipids, or multiple organ transplants.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Calculated creatinine clearance at 12 months post transplantation for patients on therapy.

Secondary outcomes

  1. Calculated creatinine clearance at 6 months Serum creatinine at 6 and 12 months post-transplantation. Graft survival at 6 and 12 months post-transplantation. Incidence of biopsy confirmed acute graft rejections at 6 and 12 months post transplantation.

07

Study locations

13 sites
  • Curitiba, PR 80730-150, Brazil
  • Rio de Janeiro, RJ 21041-030, Brazil
  • Rio de Janeiro, RJ 21941-590, Brazil
  • Porto Alegre, RS 90020-090, Brazil
  • Porto Alegre, RS 90035-903, Brazil
  • Ribeirao Preto, RS 14048-900, Brazil
  • Sao Jose do Rio Preto, SP 15015-200, Brazil
  • Sao Paulo, SP 01323-001, Brazil
  • Sao Paulo, SP 04038-002, Brazil
  • Sao Paulo, SP 05403-000, Brazil
  • Torreon, Coahuila 27000, Mexico
  • Chihuahua, Mexico
  • Mexico City DF, 14000, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 19, 2005
Start
Mar 2004
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
Mar 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00195468
First posted
Sep 19, 2005
Start date
Mar 2004
Primary completion
Nov 2006
Completion
Nov 2006
Last update
Mar 8, 2011

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Brazil, xavierl@wyeth.com
Trial Manager
principal investigator · For Mexico, gomezlj@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion